Related Experiment Video
Updated: Jan 16, 2026
07:47
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
2.2K
Expression and prognostic value of MCM2 in type B thymomas
Xin Du1, Jian Cui2, Xintao Yu2
1Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.
BMC Cancer
|October 4, 2025
Summary
MCM2 is a promising prognostic marker for thymic epithelial tumors (TETs). Higher MCM2 expression indicates better progression-free survival (PFS) in these common mediastinal malignancies.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Thymic epithelial tumors (TETs) are the most frequent mediastinal malignancies.
- Current diagnostic methods lack reliable prognostic biomarkers for TETs.
Purpose of the Study:
- To identify a novel prognostic biomarker for thymic epithelial tumors.
- To investigate the role of MCM2 as a potential prognostic marker in TETs.
Main Methods:
- Utilized mRNA microarray analysis to identify differentially expressed genes (DEGs) in 30 tumor and peritumoral tissues.
- Employed protein-protein interaction (PPI) analysis to select hub genes, identifying MCM2 as the target.
- Conducted survival and enrichment analyses, followed by validation in a separate cohort.
Main Results:
- Identified 734 DEGs, with MCM2 significantly associated with prolonged progression-free survival (PFS).
- MCM2 was confirmed as an independent prognostic factor for PFS (HR=0.26, P=0.035).
- Observed a decrease in MCM2 expression from thymoma type B1 to B3.
Conclusions:
- MCM2 serves as an independent prognostic factor for TETs.
- Higher MCM2 expression correlates with improved PFS.
- Decreasing MCM2 expression across B-type thymomas suggests its role as a favorable prognostic indicator.
